{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:09:20Z","timestamp":1787987360280,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","award":["PE00000006"],"award-info":[{"award-number":["PE00000006"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["GR- 2016-02363749"],"award-info":[{"award-number":["GR- 2016-02363749"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["GR- 2021-12373337"],"award-info":[{"award-number":["GR- 2021-12373337"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2022\/R-Multi 011"],"award-info":[{"award-number":["2022\/R-Multi 011"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2017 \/R\/18"],"award-info":[{"award-number":["2017 \/R\/18"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2022\/R-Single_064"],"award-info":[{"award-number":["2022\/R-Single_064"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022YMJXYT"],"award-info":[{"award-number":["2022YMJXYT"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P2022CMK43"],"award-info":[{"award-number":["P2022CMK43"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaut.2026.103533","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:34:31Z","timestamp":1770939271000},"page":"103533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy"],"prefix":"10.1016","volume":"159","author":[{"given":"Caterina","family":"Veroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunata","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Buscarinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Micillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Garziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisella","family":"Guerrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Battistini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ristori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Matarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana M.","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Severa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-3100","authenticated-orcid":false,"given":"Rosella","family":"Mechelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaut.2026.103533_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jaut.2026.103533_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103533_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp-2020-322941","article-title":"Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis","volume":"91","author":"Abrahamyan","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jaut.2026.103533_bib4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1352458511408991","article-title":"Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel","volume":"17","author":"Munger","year":"2011","journal-title":"Mult. Scler."},{"issue":"6578","key":"10.1016\/j.jaut.2026.103533_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jaut.2026.103533_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577935","article-title":"MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis","volume":"371","author":"Aloisi","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103533_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200460","article-title":"Epstein-Barr virus in multiple sclerosis: past, present, and future","volume":"12","author":"Wahbeh","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.jaut.2026.103533_bib8","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2424986122","article-title":"Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls","volume":"122","author":"Sattarnezhad","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2026.103533_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.665718","article-title":"The CD8 T cell-epstein-barr Virus-B cell trialogue: a central issue in multiple sclerosis pathogenesis","volume":"12","author":"Veroni","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103533_bib10","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192109","article-title":"Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells","volume":"13","author":"Hassani","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jaut.2026.103533_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425670122","article-title":"Epstein-Barr virus and the immune microenvironment in multiple sclerosis: insights from high-dimensional brain tissue imaging","volume":"122","author":"Orr","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"24","key":"10.1016\/j.jaut.2026.103533_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00980-19","article-title":"Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism","volume":"93","author":"Serafini","year":"2019","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103533_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1352458515588581","article-title":"Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins","volume":"22","author":"van Nierop","year":"2016","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jaut.2026.103533_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003220","article-title":"Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis","volume":"9","author":"Angelini","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jaut.2026.103533_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578343","article-title":"Altered EBV specific immune control in multiple sclerosis","volume":"390","author":"Munz","year":"2024","journal-title":"J. Neuroimmunol."},{"issue":"13","key":"10.1016\/j.jaut.2026.103533_bib17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1212\/WNL.0000000000001420","article-title":"Epstein-Barr virus genetic variants are associated with multiple sclerosis","volume":"84","author":"Mechelli","year":"2015","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.jaut.2026.103533_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418783122","article-title":"A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis","volume":"122","author":"Mechelli","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2026.103533_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103008","article-title":"Association of Epstein-Barr virus latently expressed genes with multiple sclerosis","volume":"52","author":"Varvatsi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/neurolint16020029","article-title":"Utilization of ocrelizumab within different treatment strategies for multiple sclerosis: a 5-Year population-based Study","volume":"16","author":"Moccia","year":"2024","journal-title":"Neurol. Int."},{"issue":"7","key":"10.1016\/j.jaut.2026.103533_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103533_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/1352458514557986","article-title":"Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE","volume":"21","author":"Kieseier","year":"2015","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib23","first-page":"242","article-title":"Obstacles and pitfalls in the PEGylation of therapeutic proteins","volume":"11","author":"Gaberc-Porekar","year":"2008","journal-title":"Curr. Opin. Drug Discov. Dev"},{"issue":"3","key":"10.1016\/j.jaut.2026.103533_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/11596970-000000000-00000","article-title":"PEGylation of interferon-beta-1a: a promising strategy in multiple sclerosis","volume":"26","author":"Kieseier","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jaut.2026.103533_bib25","first-page":"29","article-title":"Re-Evaluating the use of IFN-beta and relapsing multiple sclerosis: safety, efficacy and place in therapy","volume":"10","author":"Goldschmidt","year":"2020","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2026.103533_bib26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0091270011407068","article-title":"A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology","volume":"52","author":"Hu","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cytogfr.2014.11.005","article-title":"IFN-beta and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks","volume":"26","author":"Severa","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cytogfr.2014.10.010","article-title":"IFN-beta and multiple sclerosis: from etiology to therapy and back","volume":"26","author":"Annibali","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2026.103533_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2019.04.006","article-title":"A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis","volume":"101","author":"Severa","year":"2019","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1352458517695892","article-title":"Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients","volume":"24","author":"Giacomini","year":"2018","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jaut.2026.103533_bib32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","article-title":"Metabolic instruction of immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"issue":"9139","key":"10.1016\/j.jaut.2026.103533_bib33","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a subcutaneously in Multiple Sclerosis) Study Group","volume":"352","author":"No-Authors-Listed]","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaut.2026.103533_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023634","article-title":"Search for specific biomarkers of IFNbeta bioactivity in patients with multiple sclerosis","volume":"6","author":"Malhotra","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jaut.2026.103533_bib35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11910-011-0211-1","article-title":"Pharmacogenomics and multiple sclerosis: moving toward individualized medicine","volume":"11","author":"Comabella","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"9","key":"10.1016\/j.jaut.2026.103533_bib36","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/icb.2016.55","article-title":"Interferon-beta therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis","volume":"94","author":"Rizzo","year":"2016","journal-title":"Immunol. Cell Biol."},{"issue":"3","key":"10.1016\/j.jaut.2026.103533_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41423-022-00840-x","article-title":"Immunometabolism at the intersection of metabolic signaling, cell fate, and systems immunology","volume":"19","author":"Chi","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41590-023-01733-5","article-title":"Metabolic waypoints during T cell differentiation","volume":"25","author":"Wilfahrt","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2026.103533_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.metabol.2017.08.011","article-title":"Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration","volume":"77","author":"La Rocca","year":"2017","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.jaut.2026.103533_bib40","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/ni.3269","article-title":"Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants","volume":"16","author":"De Rosa","year":"2015","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2026.103533_bib41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.it.2012.01.010","article-title":"Metabolic pathways in T cell fate and function","volume":"33","author":"Gerriets","year":"2012","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103533_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103533_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jaut.2026.103533_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41598-019-55850-z","article-title":"The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis","volume":"10","author":"Afrasiabi","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jaut.2026.103533_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/genes11010097","article-title":"Reworking GWAS data to understand the role of nongenetic factors in MS etiopathogenesis","volume":"11","author":"Mechelli","year":"2020","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.jaut.2026.103533_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2006.10.009","article-title":"Lineage structures in the genome sequences of three Epstein-Barr virus strains","volume":"359","author":"McGeoch","year":"2007","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.jaut.2026.103533_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119605","article-title":"EBNA2 binds to genomic intervals associated with multiple sclerosis and overlaps with vitamin D receptor occupancy","volume":"10","author":"Ricigliano","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jaut.2026.103533_bib48","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity","volume":"50","author":"Harley","year":"2018","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.jaut.2026.103533_bib49","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/brain\/awx372","article-title":"Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells","volume":"141","author":"Smets","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jaut.2026.103533_bib50","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1038\/s41467-025-59813-z","article-title":"Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways","volume":"16","author":"Delecluse","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:45:23Z","timestamp":1778762723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"alternative-id":["S0896841126000119"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103533","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103533"}}